MCID: HYP066
MIFTS: 64

Hyperglycemia

Categories: Blood diseases, Metabolic diseases

Aliases & Classifications for Hyperglycemia

Summaries for Hyperglycemia

MedlinePlus : 44 Hyperglycemia means high blood sugar or glucose. Glucose comes from the foods you eat. Insulin is a hormone that moves glucose into your cells to give them energy. Hyperglycemia happens when your body doesn't make enough insulin or can't use it the right way. People with diabetes can get hyperglycemia from not eating the right foods or not taking medicines correctly. Other problems that can raise blood sugar include infections, certain medicines, hormone imbalances, or severe illnesses.

MalaCards based summary : Hyperglycemia is related to diabetes mellitus, transient neonatal, 1 and maturity-onset diabetes of the young, type 2, and has symptoms including seizures, fever and dyspnea. An important gene associated with Hyperglycemia is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Developmental Biology and Aldosterone synthesis and secretion. The drugs Zinc and Glipizide have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and brain, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 77 Hyperglycemia (also spelled hyperglycaemia or hyperglycæmia), is a condition in which an excessive... more...

Related Diseases for Hyperglycemia

Diseases related to Hyperglycemia via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 471, show less)
# Related Disease Score Top Affiliating Genes
1 diabetes mellitus, transient neonatal, 1 32.8 ABCC8 INS KCNJ11
2 maturity-onset diabetes of the young, type 2 32.8 GCK HNF1A INS PDX1
3 diabetes mellitus, permanent neonatal 32.3 ABCC8 GCK INS KCNJ11 PDX1
4 diabetes mellitus, insulin-dependent 32.0 AKR1B1 ALB GCG GCK HNF1A IAPP
5 hyperinsulinism 32.0 ABCC8 GCK IGF1 INS INSR KCNJ11
6 microvascular complications of diabetes 1 31.9 AKR1B1 IGF1 INS SST
7 hypoglycemia 31.2 ABCC8 GCG GCK INS INSR KCNJ11
8 lipid metabolism disorder 31.0 ADIPOQ INS LEP PPARG
9 microvascular complications of diabetes 5 30.8 AKR1B1 ALB IGF1 INS
10 fatty liver disease, nonalcoholic 1 30.7 ADIPOQ INS LEP
11 microvascular complications of diabetes 3 30.7 ALB INS MALAT1
12 acromegaly 30.5 IGF1 INS SST
13 gestational diabetes 30.4 ADIPOQ GCK IAPP INS INSR KCNJ11
14 vascular disease 30.4 ADIPOQ ALB INS PPARG
15 diabetic neuropathy 30.4 AKR1B1 INS LEP
16 atherosclerosis susceptibility 30.3 ADIPOQ INS PPARG
17 arteries, anomalies of 30.3 ADIPOQ ALB INS LEP PPARG
18 liver disease 30.2 ADIPOQ ALB INS LEP
19 nonalcoholic fatty liver disease 30.2 ADIPOQ INS LEP
20 fanconi-bickel syndrome 30.2 ABCC8 INS SLC2A2
21 polycystic ovary syndrome 30.2 IGF1 INS INSR LEP
22 chronic kidney failure 30.2 ADIPOQ ALB IGF1 INS LEP
23 glucose intolerance 30.2 ADIPOQ DPP4 GCG GCK IGF1 INS
24 insulin-like growth factor i 30.1 IGF1 INS INSR LEP SST
25 sleep apnea 30.1 ADIPOQ IGF1 INS LEP
26 peripheral nervous system disease 30.0 AKR1B1 ALB INS
27 islet cell tumor 30.0 IAPP INS SST
28 retinal vascular disease 30.0 AKR1B1 ALB INS
29 hyperandrogenism 30.0 IGF1 INS INSR
30 fatty liver disease 30.0 ADIPOQ INS INSR LEP MALAT1
31 uremia 29.9 ALB INS LEP
32 monogenic diabetes 29.7 ABCC8 GCK HNF1A INS KCNJ11 PDX1
33 abdominal obesity-metabolic syndrome 1 29.7 ADIPOQ INS LEP PPARG
34 hyperthyroidism 29.7 INS LEP SST
35 insulinoma 29.6 ABCC8 GCG GCK IAPP INS PDX1
36 maturity-onset diabetes of the young 29.6 ABCC8 DPP4 GCG GCK HNF1A IAPP
37 neonatal diabetes mellitus 29.6 ABCC8 GCK INS KCNJ11 PDX1 SLC2A2
38 hypertension, essential 29.5 ADIPOQ ALB INS INSR LEP
39 prediabetes syndrome 29.5 ADIPOQ ALB DPP4 GCG INS LEP
40 body mass index quantitative trait locus 11 29.3 ADIPOQ DPP4 GCG GCK IAPP IGF1
41 anorexia nervosa 29.1 ADIPOQ IGF1 LEP
42 diabetes mellitus 28.9 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
43 diabetes mellitus, noninsulin-dependent 28.9 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCG
44 mitochondrial complex iii deficiency, nuclear type 6 11.5
45 diabetes mellitus, ketosis-prone 11.4
46 diabetes and deafness, maternally inherited 11.4
47 transient neonatal diabetes mellitus 11.4
48 diabetes mellitus, insulin-dependent, 2 11.2
49 brittle diabetes 11.2
50 pancreas, dorsal, agenesis of 11.1
51 renal glucosuria 10.9
52 glycogen storage disease 0, liver 10.9
53 diabetes mellitus, insulin-dependent, 5 10.9
54 diabetes mellitus, insulin-dependent, 12 10.9
55 diabetes mellitus, insulin-dependent, 10 10.9
56 megalencephaly-capillary malformation-polymicrogyria syndrome 10.9
57 histiocytosis-lymphadenopathy plus syndrome 10.9
58 diabetes mellitus, insulin-dependent, 19 10.9
59 diabetes mellitus, transient neonatal, 2 10.9
60 diabetes mellitus, transient neonatal, 3 10.9
61 cataract 47 10.9
62 diabetes mellitus, insulin-dependent, 20 10.9
63 diabetes mellitus, insulin-dependent, 22 10.9
64 vipoma 10.9
65 pancreatic cholera 10.9
66 diabetes mellitus, 6q24-related transient neonatal 10.9
67 wdha syndrome 10.9
68 type 1 diabetes mellitus 15 10.5 GCG INS
69 munchausen by proxy 10.5 ABCC8 GCK KCNJ11
70 ischemia 10.5
71 hirata disease 10.5 ABCC8 GCG INS
72 maturity-onset diabetes of the young, type 14 10.5 ABCC8 GCK HNF1A
73 insulinomatosis and diabetes mellitus 10.5 ABCC8 INS SST
74 thiamine-responsive megaloblastic anemia syndrome 10.5 ABCC8 INS KCNJ11
75 dumping syndrome 10.5 GCG INS SST
76 acidophil adenoma 10.5 IGF1 SST
77 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.5 IGF1 INS INSR
78 secondary adrenal insufficiency 10.5 IGF1 INS
79 myocardial infarction 10.5
80 maturity-onset diabetes of the young, type 10 10.5 INS KCNJ11 PPARG
81 donohue syndrome 10.5 IGF1 INS INSR
82 acute insulin response 10.5 ABCC8 GCG INS KCNJ11
83 hyperpituitarism 10.5 IGF1 INS SST
84 pituitary infarct 10.4 IGF1 SST
85 hyperinsulinemic hypoglycemia, familial, 7 10.4 GCG INS
86 severe nonproliferative diabetic retinopathy 10.4 ALB INS
87 idiopathic edema 10.4 ADIPOQ INS PPARG
88 maturity-onset diabetes of the young, type 4 10.4 GCK HNF1A PDX1
89 endocrine organ benign neoplasm 10.4 IGF1 INS SST
90 pituitary gland disease 10.4 IGF1 INS SST
91 autosomal genetic disease 10.4 GCK HNF1A INS
92 short bowel syndrome 10.4 GCG IGF1 SST
93 renal cysts and diabetes syndrome 10.4 GCK HNF1A PDX1
94 cell type benign neoplasm 10.4 IGF1 INS SST
95 autonomic neuropathy 10.4 AKR1B1 ALB INS
96 duodenal somatostatinoma 10.4 INS SST
97 gastrointestinal system benign neoplasm 10.4 GCG IAPP INS SST
98 maturity-onset diabetes of the young, type 13 10.4 ABCC8 GCK HNF1A INS KCNJ11
99 maturity-onset diabetes of the young, type 3 10.4 GCK HNF1A INS PDX1
100 maturity-onset diabetes of the young, type 6 10.4 GCK HNF1A INS PDX1
101 maturity-onset diabetes of the young, type 7 10.4 GCK HNF1A INS PDX1
102 postgastrectomy syndrome 10.4 INS SST
103 cardiomyopathy, dilated, 1o 10.4 ABCC8 KCNJ11
104 gastrointestinal system disease 10.4 ALB GCG INS SST
105 maturity-onset diabetes of the young, type 9 10.3 GCG INS
106 proteasome-associated autoinflammatory syndrome 1 10.3 ADIPOQ ALB INS PPARG
107 lipodystrophy, congenital generalized, type 1 10.3 ADIPOQ INS LEP
108 nonalcoholic steatohepatitis 10.3 ADIPOQ INS LEP
109 alstrom syndrome 10.3 INS KCNJ11 LEP
110 pancreatic agenesis 10.3 ABCC8 GCK INS KCNJ11 PDX1
111 endocrine gland cancer 10.3 ALB GCG IAPP SST
112 apnea, obstructive sleep 10.3 ADIPOQ INS LEP
113 acute myocardial infarction 10.3
114 lipodystrophy, familial partial, type 1 10.3 INS LEP PPARG
115 complete generalized lipodystrophy 10.3 INS LEP PPARG
116 obesity-hypoventilation syndrome 10.3 ADIPOQ LEP
117 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.3 INS LEP
118 idiopathic recurrent pericarditis 10.3 ADIPOQ LEP
119 choreatic disease 10.3
120 anovulation 10.3 IGF1 INS LEP
121 hyperinsulinemic hypoglycemia 10.3 ABCC8 GCK INS INSR KCNJ11 SST
122 familial partial lipodystrophy 10.3 INS LEP PPARG
123 inherited metabolic disorder 10.3 ADIPOQ INS LEP
124 hypoxia 10.3
125 severe pre-eclampsia 10.2 ADIPOQ ALB LEP
126 protein-energy malnutrition 10.2 ALB IGF1 LEP
127 fetal macrosomia 10.2 IGF1 INS INSR LEP
128 acquired generalized lipodystrophy 10.2 ADIPOQ INS LEP PPARG
129 leukemia 10.2
130 large intestine cancer 10.2 ADIPOQ ALB IGF1 INS PPARG
131 nutritional deficiency disease 10.2 ALB IGF1 LEP
132 microvascular complications of diabetes 4 10.2
133 microvascular complications of diabetes 6 10.2
134 microvascular complications of diabetes 7 10.2
135 kidney disease 10.2
136 hormone producing pituitary cancer 10.2 IGF1 SST
137 pancreatitis 10.2
138 hypertriglyceridemia, familial 10.2
139 rere-related disorders 10.2
140 brain injury 10.2
141 3-hydroxyacyl-coa dehydrogenase deficiency 10.2 ADIPOQ GCK INS LEP PPARG
142 prader-willi syndrome 10.2 ADIPOQ GCG IGF1 INS LEP
143 stroke, ischemic 10.1
144 lymphocytic leukemia 10.1
145 paraphimosis 10.1 DPP4 SLC5A2
146 traumatic brain injury 10.1
147 neuropathy 10.1
148 hemorrhage, intracerebral 10.1
149 acute lymphocytic leukemia 10.1
150 pancreatic cancer 10.1
151 coronary artery anomaly 10.1
152 pancreatic cystadenoma 10.1 GCG IAPP INS PDX1 SLC2A2 SST
153 prostate disease 10.1 IGF1 MALAT1 PPARG
154 metabolic acidosis 10.1
155 overnutrition 10.1 ADIPOQ GCG IGF1 INS LEP PPARG
156 thrombosis 10.0
157 acanthosis nigricans 10.0 ADIPOQ IGF1 INS INSR LEP PPARG
158 breast cancer 10.0
159 exudative vitreoretinopathy 1 10.0
160 cystic fibrosis 10.0
161 aging 10.0
162 body mass index quantitative trait locus 8 10.0
163 body mass index quantitative trait locus 10 10.0
164 body mass index quantitative trait locus 7 10.0
165 body mass index quantitative trait locus 14 10.0
166 leukemia, acute lymphoblastic 10.0
167 body mass index quantitative trait locus 18 10.0
168 body mass index quantitative trait locus 19 10.0
169 acute pancreatitis 10.0
170 hypokalemia 10.0
171 brain ischemia 10.0
172 cerebral artery occlusion 10.0
173 heart disease 10.0
174 prostate cancer 10.0
175 body mass index quantitative trait locus 1 10.0
176 muscle hypertrophy 10.0
177 status epilepticus 10.0
178 depression 10.0
179 endocrine pancreas disease 9.9 ABCC8 ADIPOQ GCK IGF1 INS KCNJ11
180 neural tube defects 9.9
181 thrombophilia due to thrombin defect 9.9
182 ocular motor apraxia 9.9
183 neural tube defects, folate-sensitive 9.9
184 prostate cancer, hereditary, 8 9.9
185 coronary heart disease 1 9.9
186 prostate cancer, hereditary, 6 9.9
187 atrial fibrillation 9.9
188 glioblastoma 9.9
189 liver cirrhosis 9.9 ADIPOQ ALB LEP MALAT1 SST
190 renal cell carcinoma, nonpapillary 9.9
191 conn's syndrome 9.9
192 polyneuropathy 9.9
193 hyperuricemia 9.9
194 transient cerebral ischemia 9.9
195 lactic acidosis 9.9
196 adenoma 9.9
197 meningitis 9.9
198 encephalopathy 9.9
199 hepatocellular carcinoma 9.8
200 fish-eye disease 9.8
201 galactosemia 9.8
202 helicobacter pylori infection 9.8
203 preaxial hallucal polydactyly 9.8
204 mycobacterium tuberculosis 1 9.8
205 graft-versus-host disease 9.8
206 pulmonary hypertension 9.8
207 burns 9.8
208 cataract 9.8
209 hematopoietic stem cell transplantation 9.8
210 hepatitis 9.8
211 neutropenia 9.8
212 spinal cord injury 9.8
213 cardiac arrest 9.8
214 dementia 9.8
215 methylmalonic acidemia 9.8
216 epilepsy 9.8
217 adenocarcinoma 9.8
218 fibrosarcoma 9.8
219 aortic aneurysm 9.8
220 lymphopenia 9.8
221 periodontitis 9.8
222 myeloid leukemia 9.8
223 acute graft versus host disease 9.8
224 fasting hypoglycemia 9.8
225 seizure disorder 9.8
226 head injury 9.8
227 aortic aneurysm, familial abdominal, 1 9.7
228 alzheimer disease 9.7
229 colorectal cancer 9.7
230 lipodystrophy, familial partial, type 2 9.7
231 osteoporosis 9.7
232 ovarian cancer 9.7
233 smith-magenis syndrome 9.7
234 tuberous sclerosis 1 9.7
235 myeloma, multiple 9.7
236 pulmonary alveolar microlithiasis 9.7
237 graves disease 1 9.7
238 werner syndrome 9.7
239 leukemia, acute myeloid 9.7
240 yemenite deaf-blind hypopigmentation syndrome 9.7
241 homocysteinemia 9.7
242 cervical cancer 9.7
243 anxiety 9.7
244 ichthyosis prematurity syndrome 9.7
245 bone mineral density quantitative trait locus 8 9.7
246 bone mineral density quantitative trait locus 15 9.7
247 gastric cancer 9.7
248 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.7
249 hyperproinsulinemia 9.7
250 sclerosing cholangitis, neonatal 9.7
251 angina pectoris 9.7
252 acute leukemia 9.7
253 colorectal adenoma 9.7
254 congestive heart failure 9.7
255 glycogen storage disease 9.7
256 hydrocephalus 9.7
257 osteoarthritis 9.7
258 autoimmune pancreatitis 9.7
259 hypophosphatemia 9.7
260 sexual disorder 9.7
261 lymphoma 9.7
262 sensorineural hearing loss 9.7
263 coronary thrombosis 9.7
264 diabetic polyneuropathy 9.7
265 diarrhea 9.7
266 tuberous sclerosis 9.7
267 neuroendocrine tumor 9.7
268 melanoma 9.7
269 dental caries 9.7
270 arteriosclerosis 9.7
271 iron metabolism disease 9.7
272 reflex epilepsy 9.7
273 prostatic adenoma 9.7
274 periodontal disease 9.7
275 carcinosarcoma 9.7
276 movement disease 9.7
277 pneumonia 9.7
278 central pontine myelinolysis 9.7
279 retinal degeneration 9.7
280 influenza 9.7
281 bacterial meningitis 9.7
282 acute respiratory distress syndrome 9.7
283 congenital hydrocephalus 9.7
284 degos 'en cocarde' erythrokeratoderma 9.7
285 desmoplastic infantile astrocytoma 9.7
286 glioma 9.7
287 sudden sensorineural hearing loss 9.7
288 glycogen storage disease type 0 9.7
289 cerebral hypoxia 9.7
290 dysphagia 9.7
291 rapidly involuting congenital hemangioma 9.7
292 moderate and severe traumatic brain injury 9.7
293 pancreas disease 9.6 ABCC8 ALB DPP4 GCG IGF1 INS
294 atrial standstill 1 9.6
295 autoimmune disease 9.6
296 alopecia, androgenetic, 1 9.6
297 hypercarotenemia and vitamin a deficiency, autosomal dominant 9.6
298 multiple endocrine neoplasia, type i 9.6
299 esophageal cancer 9.6
300 systemic lupus erythematosus 9.6
301 motion sickness 9.6
302 myositis 9.6
303 pheochromocytoma 9.6
304 porphyria cutanea tarda, type i 9.6
305 porphyria cutanea tarda 9.6
306 hutchinson-gilford progeria syndrome 9.6
307 pulmonary hypertension, primary, 1 9.6
308 retinoblastoma 9.6
309 schizophrenia 9.6
310 tetralogy of fallot 9.6
311 vertigo, benign recurrent 9.6
312 central hypoventilation syndrome, congenital 9.6
313 celiac disease 1 9.6
314 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.6
315 enterocolitis 9.6
316 hemochromatosis, type 1 9.6
317 lymphoma, hodgkin, classic 9.6
318 hydrocephalus, congenital, 1 9.6
319 hypoascorbemia 9.6
320 laron syndrome 9.6
321 spondylocarpotarsal synostosis syndrome 9.6
322 kearns-sayre syndrome 9.6
323 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 9.6
324 prostatic hyperplasia, benign 9.6
325 asthma 9.6
326 horns in sheep 9.6
327 hyperinsulinemic hypoglycemia, familial, 2 9.6
328 hyperinsulinemic hypoglycemia, familial, 3 9.6
329 lymphoma, non-hodgkin, familial 9.6
330 gastrointestinal stromal tumor 9.6
331 pulmonary disease, chronic obstructive 9.6
332 meningioma, familial 9.6
333 headache associated with sexual activity 9.6
334 autoimmune disease 1 9.6
335 hypertension, diastolic 9.6
336 carney complex variant 9.6
337 aplastic anemia 9.6
338 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.6
339 hyperinsulinemic hypoglycemia, familial, 5 9.6
340 hyperinsulinemic hypoglycemia, familial, 4 9.6
341 malaria 9.6
342 intraocular pressure quantitative trait locus 9.6
343 lung cancer susceptibility 3 9.6
344 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.6
345 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.6
346 blood group, gerbich system 9.6
347 peripheral vascular disease 9.6
348 alcohol abuse 9.6
349 alopecia 9.6
350 bipolar disorder 9.6
351 breast reconstruction 9.6
352 cerebral hemorrhage 9.6
353 diabetic foot ulcers 9.6
354 hepatitis b 9.6
355 pancreatic ductal adenocarcinoma 9.6
356 pemphigus foliaceus 9.6
357 retinal ischemia 9.6
358 somatostatinoma 9.6
359 hyperphosphatemia 9.6
360 androgenic alopecia 9.6
361 diabetic encephalopathy 9.6
362 limb ischemia 9.6
363 renal fibrosis 9.6
364 adrenal gland pheochromocytoma 9.6
365 infective endocarditis 9.6
366 basal ganglia calcification 9.6
367 obstructive nephropathy 9.6
368 mitochondrial complex iii deficiency 9.6
369 osteomyelitis 9.6
370 parotitis 9.6
371 endocarditis 9.6
372 pre-eclampsia 9.6
373 methemoglobinemia 9.6
374 malignant hypertension 9.6
375 hand, foot and mouth disease 9.6
376 dissociative disorder 9.6
377 respiratory failure 9.6
378 keratomalacia 9.6
379 pituitary apoplexy 9.6
380 spinal meningioma 9.6
381 pulmonary edema 9.6
382 autonomic nervous system disease 9.6
383 diabetic angiopathy 9.6
384 lyme disease 9.6
385 cortical blindness 9.6
386 gastroparesis 9.6
387 pancytopenia 9.6
388 hemolytic-uremic syndrome 9.6
389 balanitis 9.6
390 porphyria 9.6
391 diabetic cataract 9.6
392 cholestasis 9.6
393 eclampsia 9.6
394 acute closed-angle glaucoma 9.6
395 benign paroxysmal positional nystagmus 9.6
396 epicondylitis 9.6
397 oligospermia 9.6
398 suppurative cholangitis 9.6
399 neuroleptic malignant syndrome 9.6
400 hypothyroidism 9.6
401 rheumatic disease 9.6
402 pericarditis 9.6
403 hepatitis c 9.6
404 gaucher's disease 9.6
405 hyperostosis 9.6
406 thrombocytosis 9.6
407 focal epilepsy 9.6
408 colon adenocarcinoma 9.6
409 opiate dependence 9.6
410 pulmonary tuberculosis 9.6
411 cockayne syndrome 9.6
412 glioblastoma multiforme 9.6
413 interstitial lung disease 9.6
414 gingival overgrowth 9.6
415 gallbladder cancer 9.6
416 central nervous system lymphoma 9.6
417 vaccinia 9.6
418 teratoma 9.6
419 pseudomyxoma peritonei 9.6
420 choriocarcinoma 9.6
421 plexopathy 9.6
422 protein c deficiency 9.6
423 mouth disease 9.6
424 avian influenza 9.6
425 secretory meningioma 9.6
426 brain edema 9.6
427 arteriolosclerosis 9.6
428 infertility 9.6
429 retinal disease 9.6
430 acquired immunodeficiency syndrome 9.6
431 connective tissue disease 9.6
432 cerebrovascular disease 9.6
433 parasagittal meningioma 9.6
434 carotid artery occlusion 9.6
435 mediastinitis 9.6
436 peritonitis 9.6
437 lung disease 9.6
438 subacute delirium 9.6
439 perinatal necrotizing enterocolitis 9.6
440 vascular dementia 9.6
441 lupus erythematosus 9.6
442 dermatophytosis 9.6
443 pemphigus 9.6
444 diabetes insipidus 9.6
445 cholangitis 9.6
446 hypereosinophilic syndrome 9.6
447 acid sphingomyelinase deficiency 9.6
448 juvenile hereditary hemochromatosis 9.6
449 carcinoid syndrome 9.6
450 cytokine deficiency 9.6
451 exencephaly 9.6
452 microscopic polyangiitis 9.6
453 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 9.6
454 primary central nervous system lymphoma 9.6
455 tuberculous meningitis 9.6
456 clopidogrel resistance 9.6
457 multiple endocrine neoplasia 9.6
458 paraneoplastic syndromes 9.6
459 cerebral aneurysms 9.6
460 dysautonomia 9.6
461 extrapontine myelinolysis 9.6
462 neonatal hypoxic and ischemic brain injury 9.6
463 toxic oil syndrome 9.6
464 paracetamol poisoning 9.6
465 methanol poisoning 9.6
466 pneumococcal meningitis 9.6
467 cardiogenic shock 9.6
468 acute adrenal insufficiency 9.6
469 acquired metabolic disease 9.0 ABCC8 ADIPOQ ALB DPP4 GCG GCK
470 glucose metabolism disease 9.0 ABCC8 ADIPOQ ALB DPP4 GCG GCK
471 maturity-onset diabetes of the young, type 1 8.9 ABCC8 ADIPOQ ALB DPP4 GCG GCK

Graphical network of the top 20 diseases related to Hyperglycemia:



Diseases related to Hyperglycemia

Symptoms & Phenotypes for Hyperglycemia

UMLS symptoms related to Hyperglycemia:


seizures, fever, dyspnea, edema, cachexia, vertigo, headache, syncope, cyanosis, icterus, signs and symptoms, signs and symptoms, digestive, hot flushes, symptoms

MGI Mouse Phenotypes related to Hyperglycemia:

47 (showing 13, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ABCC8 ADIPOQ AKR1B1 ALB DPP4 GCK
2 growth/size/body region MP:0005378 10.36 ADIPOQ AKR1B1 DPP4 GCK HNF1A IAPP
3 endocrine/exocrine gland MP:0005379 10.32 ABCC8 ADIPOQ ALB DPP4 GCK HNF1A
4 behavior/neurological MP:0005386 10.25 ADIPOQ AKR1B1 HNF1A INS INSR KCNJ11
5 adipose tissue MP:0005375 10.18 ADIPOQ HNF1A IGF1 INS INSR KCNJ11
6 mortality/aging MP:0010768 10.17 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
7 digestive/alimentary MP:0005381 10.1 ALB HNF1A INS INSR LEP PDX1
8 liver/biliary system MP:0005370 10.07 ADIPOQ ALB GCK HNF1A INS INSR
9 integument MP:0010771 10.01 ADIPOQ HNF1A IGF1 INS KCNJ11 LEP
10 muscle MP:0005369 10 ADIPOQ ALB HNF1A IGF1 INS INSR
11 renal/urinary system MP:0005367 9.73 ADIPOQ AKR1B1 ALB GCK HNF1A IGF1
12 no phenotypic analysis MP:0003012 9.7 ABCC8 HNF1A INS KCNJ11 PDX1 PPARG
13 skeleton MP:0005390 9.32 ADIPOQ AKR1B1 HNF1A IAPP IGF1 INS

Drugs & Therapeutics for Hyperglycemia

Drugs for Hyperglycemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 867, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
2
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2 29094-61-9 3478
3
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Not Applicable 361442-04-8 11243969
4
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
5
Insulin glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
6
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
7
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 62-31-7, 51-61-6 681
8
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Not Applicable 207748-29-6
9
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Not Applicable 169148-63-4 5311023
10
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56180-94-0 441184
11
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
12
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 116094-23-6 16132418
13
Curcumin Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 458-37-7 969516
14
Celecoxib Approved, Investigational Phase 4,Phase 1,Phase 2 169590-42-5 2662
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
16
Parecoxib Approved Phase 4 198470-84-7
17
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
18
Nitric Oxide Approved Phase 4,Phase 2,Not Applicable 10102-43-9 145068
19
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
20
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
21
Ramipril Approved Phase 4,Phase 3 87333-19-5 5362129
22
Amlodipine Approved Phase 4 88150-42-9 2162
23
Clonidine Approved Phase 4 4205-90-7 2803
24
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
25
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
26
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
27
Atenolol Approved Phase 4 29122-68-7 2249
28
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
29
Doxazosin Approved Phase 4 74191-85-8 3157
30
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
31
Valsartan Approved, Investigational Phase 4,Phase 1,Phase 2 137862-53-4 60846
32
Glucagon Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16941-32-5
33
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-23-7 5754
34
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-03-3
35
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
36
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
37
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
38
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
39
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
40
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 122320-73-4 77999
41
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
42
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
43
Insulin Lispro Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 133107-64-9
44
Liraglutide Approved Phase 4,Phase 3,Phase 2,Not Applicable 204656-20-2 44147092
45
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
48
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 98-92-0 936
49
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 51-43-4 5816
50
Racepinephrine Approved Phase 4,Phase 3,Not Applicable 329-65-7 838
51
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
52
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 24280-93-1 446541
53
Fenofibrate Approved Phase 4,Phase 2,Phase 3,Not Applicable 49562-28-9 3339
54
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134523-00-5 60823
55
Linagliptin Approved Phase 4,Phase 3,Not Applicable 668270-12-0 10096344
56
Gliclazide Approved Phase 4,Phase 2,Not Applicable 21187-98-4 3475
57
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
58
Propranolol Approved, Investigational Phase 4 525-66-6 4946